Jessica Cescutti

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( <scp>EASE</scp> ‐1)

Thomas R. Pieber, Susanne Famulla, Jens Eilbracht et al. · Diabetes Obesity and Metabolism · 2015 · 162 citations · Full text

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARLINA</scp> ‐ <scp>T2D</scp> trial

Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic et al. · Diabetes Obesity and Metabolism · 2017 · 148 citations · Full text

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial

S. Ross, Claus Thamer, Jessica Cescutti et al. · Diabetes Obesity and Metabolism · 2015 · 48 citations · Full text

Empagliflozin Twice Daily, Metabolic Syndrome, Diabetes Management +11

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D^™ trial

Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic et al. · Diabetes and Vascular Disease Research · 2015 · 42 citations · Full text

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Ahmad Awada, Herlinde Dumez, Philippe Aftimos et al. · Investigational New Drugs · 2015 · 29 citations · Full text